Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Determine the Safety and Tolerability of Whole Brain Radiotherapy (WBRT) or Proton Craniospinal Irradiation (PCSI) With Multiple Doses of Rhenium-186 NanoLiposome (186RNL, REYOBIQ) Administered Via Intraventricular Catheter for Leptomeningeal Metastases

NCT07674693 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT07674693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07674693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Determine the Safety and Tolerability of Whole Brain Radiotherapy (WBRT) or Proton Craniospinal Irradiation (PCSI) With Multiple Doses of Rhenium-186 NanoLiposome (186RNL, REYOBIQ) Administered Via Intraventricular Catheter for Leptomeningeal Metastases
Lead sponsor
NYU Langone Health
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
July 31, 2031
Enrollment
29 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

leptomeningeal metastases